Dear [Recipient Title] [Recipient Last Name],

Join us at ENDO 2024! Don't miss our

Science & Innovation Theater

featuring

Paltusotine: A Novel Investigational Oral Small Molecule Somatostatin Receptor Ligand For Acromegaly

Saturday
June 1st
3:15 pm EDT

Science &
Innovation
Theater #2

Presented by Kevin C.J. Yuen MBChB, MD, FRCP, FACE, Barrow Neurological Institute in Phoenix, AZ

Join us on Monday, June 3rd, from 12:00 pm to 1:30 pm EDT at the ENDOExpo Poster Area (BCEC) to discover the latest advancements in our clinical development programs, highlighted by four late-breaking abstracts.

Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical CAH	MON-677
MON-677

Atumelnant (CRN04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With ACTH-dependent Cushing Syndrome	MON-680
MON-680

Efficacy and Safety of Once-Daily Oral Paltusotine in Medically Untreated Patients With Acromegaly: Results from a Phase 3, Randomized, Placebo-Controlled Study	MON-694
MON-694

Long-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment of Patients With Acromegaly	MON-695
MON-695

Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide	MON-156
MON-156

We invite you to learn about our advancements in endocrinology at

BOOTH #915

We eagerly anticipate your presence at ENDO 2024!

Warm regards,
Crinetics Pharmaceuticals

This is being sent on behalf of Crinetics Pharmaceuticals and is not part of ENDO 2024 as planned by The Endocrine Society. This company is neither sponsored nor endorsed by The Endocrine Society.

Contact | Privacy Policy | Unsubscribe